Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study investigates the efficacy and the safety of Lanthanum Carbonate for the reduction
of urinary oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis.